Acne vulgaris, a condition that can affect people at any age, is the most common cause of referral to a dermatologist. Isotretinoin (ITT) is the most effective treatment available, but serious adverse effects, including a possible association with depression and suicide, limit its use. We review the current literature regarding the association of ITT with depression and suicide. Case reports and database studies show a clear association, and this association is biologically plausible. Although prospective studies have opposite results, limitations make them unsuitable to identify a subgroup of patients who may be at risk of developing depression or suicidal ideation with ITT. Overall, it seems some people might be at risk, particularly those with a personal or family history of mental disorder, but further studies are needed to identify those patients who would benefit from an early referral to a mental health professional when ITT is initiated. Currently, no conclusions can be drawn, and it seems appropriate to regularly screen all patients on ITT for depressive symptoms and suicidal ideation and promptly refer them to a mental health professional if any are found.
Acne vulgaris has impact on emotional and social well-being in addition to physical pain and scarring. In fact, it seems to have greater adverse effects on mood than other chronic cutaneous disorders, such as psoriasis and alopecia. 1 Acne causes shyness and social isolation 2 and is associated with higher levels of trait and state anxiety 3 and higher levels of social anxiety, 4 ,5 depression, 6, 7 obsessive/compulsive symptoms, 8 suicidal ideation and suicide attempts, [9] [10] [11] [12] and body dysmorphic disorder 13 ; in addition, it has marked effects on quality of life as great as asthma, epilepsy, diabetes, back pain, or arthritis. 14 The psychological impact of acne has been particularly well documented in adolescents. 2 There are several treatments available for acne, but only isotretinoin (ITT) treats all primary aetiological factors, reducing sebaceous gland size, inhibiting formation of new comedones, reducing growth of Propionibacterium acnes, and decreasing inflammation. 12, 15 At least half of all patients treated with ITT permanently clear after 1 treatment course. 16 Because of potential serious side effects, ITT is only indicated for acne when it is severe and does not respond to oral or topical antibiotic or topical retinoid (recalcitrant acne) or for acute-onset severe acne with systemic complaints (acne fulminans) 17 ; nevertheless, it is being increasingly prescribed for mild or moderately severe acne. 18 ITT is associated with significant adverse effects, the most common of which are dry mucous membranes, headache, alopecia, hypertriglyceridemia, and joint and muscle pain. 15 It has also been linked to psychiatric side effects-namely, depression and suicidality-although this association remains controversial. A 2012 review by Bremner and colleagues 19 indicates strong evidence in the psychiatric literature of an association between ITT and psychiatric side effects; however, dermatological research suggests acne may be an independent risk factor for depression, and ITT may improve depression by treating acne and improving self-image.
In this article, we review the literature published during the past 10 years, a period that includes, to the authors' best knowledge, all prospective studies, and discuss whether there is evidence that ITT is associated with depression and suicidality and how this may translate to clinical practice. We also discuss limitations of current research.
Methods
Medline and PubMed were searched for results from 2005 to December 2016 for the keywords isotretinoin, depression, depressive disorders, suicide, and suicidal ideation. Articles related to ITT and its relation with depression or suicide, as well as the biological plausibility of such relation, were selected. No study was excluded. All studies found were reviewed-namely, previous reviews, case reports (including challenge/rechallenge cases), database analyses, and retrospective and prospective studies. At the end of this process, we had found 61 studies, of which 24 were original studies meeting all criteria for inclusion (4 case reports/series and 3 database, 5 retrospective, and 12 prospective studies).
Results

Case Reports
Case reports (Table 1 ) are important to draw attention toward potential rare or idiosyncratic side effects of drugs. From 1982, the year ITT was introduced, to 2000, 431 cases of depression, suicidal ideation, suicide attempts, or suicide associated with ITT were reported to the Food and Drug Administration (FDA) 20 ; 37 patients committed suicide and 110 patients needed inpatient treatment for depression. 21 Case reports have shown not only a temporal association between the development of depression and ITT [22] [23] [24] but also reduction or remission when the drug was withdrawn and recurrence on rechallenge. 20, 22 Case reports are becoming less frequent in favor of larger database, retrospective, and prospective studies, but they provide strong evidence of a possible causal relation between ITT and depression. A recent case series of 9 patients found a possible association of development of depressive symptoms with family history of affective disorder and prior episode of mental disorder. 25 There have also been case reports of mania 26 and psychosis, 21 but these are far less common.
Database studies
Database studies ( 20 In the United Kingdom, from 1998 to 2011, ITT was among the top 5 drugs for reports of depressive disorders. 28 In Canada from 1983 to 2003, 25% of adverse events associated with ITT were psychiatric. 29 Finally, in France, a case/no-case study of the pharmacovigilance database from 2007 to 2011 identified ITT as the only drug with significant reporting odds ratio for depression. 30 The European Union's (EU) Pharmacovigilance Risk Assessment Committee is currently preparing a review of the information of pharmacovigilance databases across all countries of the EU and has also requested its member states information regarding completed or ongoing interventional studies, epidemiological studies, meta-analyses and systematic reviews, published literature, and spontaneous case reports.
Retrospective Studies
Retrospective studies (Table 3) suggest there may be an association of ITT with depression or suicidality, but these studies are often underpowered and barely reach statistical significance. A crossover study showed an association between ITT and depression, 31 but it is not without shortfalls. 32 Another study has shown a slight increase in suicide attempts, but the authors note that suicide risk was already rising in the months prior to initiating ITT, so no association between the 2 factors could be established. 33 A chart review of patients started on ITT found 'mood changes' in 7.5% of 1743 patients, 13 of whom had to stop ITT, but there was no association with suicidal ideation or suicide. 34 Another study, looking at military personnel, compared ITT users to a control group of people with psoriasis and found that the ITT group were more frequent users of mental health services 35 ; however, it is not clear if use was already higher prior to ITT, which would not be surprising because ITT is prescribed to severe cases of acne and there was no indication of severity in the psoriasis group. Finally, a chart review of 300 patients with bipolar disorder found 10 patients on ITT, noting that 9 experienced worsening of mood and suicidal ideation and 8 experienced improvement after stopping ITT. 
Prospective Studies
Strong evidence for an association of ITT with depression or suicidality could be provided by controlled, randomised, double-blind prospective studies, but although prospective studies are becoming increasingly common, none fulfills all these criteria (Table 4) . Furthermore, comparison between the studies is difficult because of the various measurements used (Table 5 ). We found 12 prospective studies, 5 of which had a control group. Of the 7 studies without control, the majority found an improvement in depression, 2,37-40 suicidal ideation, 37 and/or anxiety. 2 One study focusing on impaired anger management and anger found no detrimental effect on depressive symptoms. 41 In some of these studies, there were some isolated instances of depression with no impact on the statistical analysis. 37, 38 One study, however, found a significant increase in depression. 1 The 5 studies with a control group are not randomised. Two show improvement in depression and anxiety 42, 43 ; 1 shows that despite improvement, depression and anxiety are still significantly higher in ITT as opposed to the control group 42 ; and the other shows improvement in both groups but significantly higher in the ITT group. 43 The other 3 controlled studies show no association of ITT and depression [44] [45] [46] or anxiety. 45 
Biological Plausibility
Oral synthetic retinoids, such as ITT, belong to a group of molecules derived from vitamin A. The biologically active form of retinoic acid (RA) is all-trans RA, which has a high affinity to retinoic acid receptors and binds them to control gene transcription, differentiation, proliferation, and apoptosis. 40 ITT is an isomer of RA (13-cis RA) with a longer half-life. 47 Like other retinoids, its biological activity is achieved after conversion to alltrans RA. 48 Despite the importance of vitamin A for the development and function of the central nervous system (CNS), excess vitamin A has been shown to cause lethargy, depression, cyclothymia, insomnia and hypersomnolence, skin changes, hair loss, headache, bone and joint pain, and liver enlargement, and it was also noted that it could cause irritability and frank psychosis. 19, 29 This clinical picture loosely corresponds to the major side effects of retinoid treatment. 19 An unusual form of vitamin A overexposure is pibloktoq, a syndrome found in people living in the Arctic Circle that includes depression and explosive outbursts, 19 which, to the knowledge of the authors, has not been described with ITT treatment.
ITT can, theoretically, cause changes in the CNS because it crosses the blood-brain barrier (Table 6 ). In fact, it has been shown to increase depression-related behaviours in both mice and rats, 49, 50 although not in all studies of the adult rat. 51, 52 It has been described to disrupt function of the hippocampus, corpus striatum, and frontal cortex, particularly the orbitofrontal cortex (a region often associated with depression). 29 These effects may be indirect, via the dopaminergic, serotoninergic, and, possibly, noradrenergic systems, 19, 46, 53 and although it has been shown that the number of serotoninergic cells arising from the raphe nuclei remains unchanged, it is possible that serotoninergic input to the hippocampus is impaired by chronic ITT treatment. 49, 50 Furthermore, retinoids presumably affect trophic processes in the brain and may participate in the reduction of hippocampal volume and contribute to the development of psychiatric illnesses. 29, 53 Another factor that should be considered when considering a biological theory is genetic vulnerability. Some authors advocate gene-environment interaction, with ITT being an undifferentiated environmental stressor and its effects being modulated by the various types of genetic vulnerability of the exposed individuals, 54 a model currently proposed for 31 
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Slight increase in suicide attempts ITT, isotretinoin. several psychiatric disorders. Alzoubi and colleagues 55 found that the T allele of the rs9303285, a genetic polymorphism in the retinoic acid receptor α, was protective against the development of depression in patients treated with ITT.
Discussion
Overall, case reports, database studies, and retrospective studies show a possible association between ITT and depression. Prospective studies, on the other hand, show no association or, in some studies, improvement of depressive symptoms.
There also appear to be several possible biological mechanisms for this association. Overall, reviews have shown that depression and suicide appear commonly 1 to 2 months after treatment initiation. This suggests that the biological mechanism may not be via immediate influence of ITT on a crucial neurotransmitter or other signal pathway but may be through a secondary system or possibly alteration of neuroplasticity or a metabolic process known to be influenced by RA. Alternatively, changes in neurochemical systems may occur more rapidly, but it may take weeks or months before a behavioural effect is seen, as is the case with antidepressants.
Furthermore, despite the results of prospective studies, challenge/rechallenge case reports provide a very strong indication that there is at least a subset group of patients with vulnerability to ITT. Such patients are probably excluded from most prospective studies, which remove patients with a personal or family history of mental disorder (Table 1 ). In addition, it is possible that successful treatment with ITT may improve depressive symptoms in severe cases of acne (possibly by improving self-image), obscuring the fact that the drug is negatively affecting a small number of patients. In fact, some of the prospective studies describe cases of depression with ITT, although globally there was no association. The sample sizes are not large enough to assess this question.
In many studies, depression rates before treatment are much lower than in the general population, 56 which may be a consequence of removing people with depressive symptoms (past or present) from studies. Furthermore, many studies are performed in adolescents, a group known to have a higher background prevalence of depression, 46 and ITT is usually prescribed to patients with severe acne, which is itself associated with depression. 44 This makes it difficult to identify small increases of depression rates if they were to occur.
The different views of dermatologists and psychiatrists described in the literature could be a result of recruitment bias. Dermatologists may not have been aware of the occurrence of psychiatric disorders. On the other hand, loss of energy and fatigue can be related to lethargy, a side effect of ITT; this may explain why somatic features of depression may not improve with therapy, 57 a possibility psychiatrists need to be aware of. Then again, it is possible that in many cases, depression is an unrelated event, caused by acne or a number of other factors. This notion, however, is challenged by the challenge/ rechallenge case reports, which point to, at least, an idiosyncratic reaction, as well as by reports that higher doses of ITT are associated with a greater risk of depression.
One major limitation of current literature is the lack of randomised and blinded controlled studies. The FDA recommended such studies in 2000 but in 2002 concluded it would difficult to adequately blind because of the dry skin side effects of ITT. Authors have suggested using topical ITT as a control that dries the skin but has minimal absorption into the bloodstream. 19 Furthermore, the use of a placebo control group poses ethical questions. Other limitations are retrospective studies based on incomplete databases, small sample size, use of different measurements, and no agreement over standardised assessments for acne, depression, or suicidality (Table 2) .
Although at the present moment, no clear conclusion can be drawn, if dermatologists find depressive symptoms or suicidal ideation in a patient on ITT, prompt referral to a mental health professional should be the first step, and appropriate therapy should be started, in a multidisciplinary approach. 58 It may also be appropriate to reduce or cease ITT if depressive symptoms are moderate to severe. 29 However, although it is imperative to screen for them, 25 depressive symptoms and especially a personal or family history of mental illness should not be a reason for denying ITT to patients with severe acne. 17, 29, 59 In such cases, it may be appropriate to refer to a mental health professional, who can monitor the patient during treatment with ITT.
It is clear that an association between ITT and depression exists. It seems ITT may improve depressive symptoms in patients with severe acne, if treatment is successful. However, in a subset of patients, most likely those with a personal or family history of mental disorder or other genetic predisposition, depression may be caused or worsened by ITT. It is important that the risk factors for this side effect are known so that patients at risk may be easily identified by the dermatologist (possibly through the use of a standardised questionnaire) and referred to a psychiatric evaluation before and during treatment with ITT. 
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